drugset
drugset / Trial / NCT07111988

Valbenazine in Obsessive Compulsive Disorder

NCT07111988 ↗

Phase 2 Not yet recruiting 30 enrolled University of Chicago Neurocrine Biosciences · collab
RandomizedCrossoverQuadruple-blindTreatment

Summary

The primary aim of the study is to examine the efficacy and safety of valbenazine in adults with moderate to severe obsessive-compulsive disorder (OCD).

Timeline

Start
2026-06
Primary completion
2027-12
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Valbenazine Small molecule 80 mg —

Indications

obsessive-compulsive disorder